TACE Combined With Penpulimab and Anlotinib for Advanced HCC
Status:
Not yet recruiting
Trial end date:
2024-03-31
Target enrollment:
Participant gender:
Summary
The purpose of this multicenter, dual-cohort, prospective real-world study is to explore the
efficacy and safety of penpulimab and anlotinib combined with or without TACE, as well as the
optimum interval of the combination of penpulimab and anlotinib with TACE in advanced HCC
patients.